Results 131 to 140 of about 91,007 (250)

Engineered B7‐H3 Binding in Modular Gp2 Miniproteins

Biotechnology and Bioengineering, EarlyView.
ABSTRACT B7‐H3, an important immune checkpoint modulator of T‐cell function, is a tumor vasculature biomarker and is overexpressed in a variety of cancers. Its expression is associated with tumor growth, metastasis, and poor clinical prognosis, which makes B7‐H3 an appealing target for diagnostics and therapeutics.
Abbigael Harthorn, Hannah K. Windsor, Zachary Schmitz, Nathaniel Cheung, Ebube Agwaramgbo, Benjamin J. Hackel   +5 more
wiley   +1 more source

PI-RADS v2.1 Combined With Prostate-Specific Antigen Density for Detection of Prostate Cancer in Peripheral Zone. [PDF]

Front Oncol, 2022
Wen J, Tang T, Ji Y, Zhang Y.
europepmc   +1 more source

Cold atmospheric plasma‐mediated tumor microenvironment remodeling for cancer treatment

BMEMat, EarlyView.
Schematic presentation of CAP‐mediated TME remodeling. This review summarizes recent efforts in cold atmospheric plasma (CAP) application in cancer treatment, highlighting the anticancer potential of CAP, molecular mechanisms, and future perspectives for further improvement and clinical translation.
Israr Khan, Qiujie Fang, Cao Fei, Ziyuan Wang, Zhaowei Chen, Guojun Chen, Zhiming Xu, Shu Xu, Zhitong Chen   +8 more
wiley   +1 more source

Combining Multiparametric Magnetic Resonance Imaging and Prostate-Specific Antigen Density in Selecting Patients for Prostate Biopsy. [PDF]

Cureus
Derimachkovski G, Georgiev G, Draginov K, Petkov B, Rumenov V, Stoilov D, Tomov Y, Vasilev V, Yanev K.   +8 more
europepmc   +1 more source

Fiber‐type soft bioelectronics for wearable and implantable sensing and therapy

BMEMat, EarlyView.
Fiber‐type soft bioelectronics are emerging as versatile platforms for wearable and implantable health monitoring and therapeutic applications. These bioelectronics use organic and inorganic matrices combined with advanced fillers, which feature high conductivity, electrochemical sensitivity, softness, and biocompatibility.
Haneul Kim, Hak Yong Kim, Ja Hoon Koo, Gi Doo Cha, Dae‐Hyeong Kim, Hye Jin Kim   +5 more
wiley   +1 more source

Additional predictive value of systemic inflammation indices beyond prostate specific antigen density for clinically significant prostate cancer. [PDF]

BMC Urol
Sulhan H, Kalyenci B.
europepmc   +1 more source

The role of prostate-specific antigen density and negative multiparametric magnetic resonance imaging in excluding prostate cancer for biopsy-naïve men: clinical outcomes from a high-volume center in China. [PDF]

Asian J Androl, 2022
Zhang CC, Tu X, Lin TH, Cai DM, Yang L, Nie L, Qiu S, Liu ZH, Jin K, Li JK, Xiong XY, Yang L, Wei Q.   +12 more
europepmc   +1 more source

Nanomaterials‐mediated glycolysis rewriting to potentiate tumor immunotherapy

BMEMat, EarlyView.
This review systematically summarizes cutting‐edge advances in glycolysis‐rewiring nanomedicines, emphasizing their mechanisms in reversing immunosuppression and reinvigorating antitumor immune responses. Challenges in clinical translation and future directions for designing multifunctional metabolic‐immune modulators are also critically discussed ...
Zilin Ma, Songyan Li, Jie Yan, Xuechun Wang, Wen Zhao, Yunxuan Song, Dongdong Liu, Jianwei Jiao, Xiuying Duan, Guiqiang Zhang   +9 more
wiley   +1 more source

Diagnostic Value of Transabdominal Ultrasound-based Versus Magnetic Resonance Imaging-based Prostate-specific Antigen Density for Clinically Significant Prostate Cancer. [PDF]

Eur Urol Open Sci
Xu Z, Song H, Huang H, Fu M, Tang Y, Zhang P, Zhang G, Li J.   +7 more
europepmc   +1 more source

Determination of Whether Apex or Non-Apex Prostate Cancer Is the Best Candidate for the Use of Prostate-Specific Antigen Density to Predict Pathological Grade Group Upgrading and Upstaging after Radical Prostatectomy. [PDF]

J Clin Med, 2023
Huang C, He S, He Q, Gong Y, Song G, Zhou L.   +5 more
europepmc   +1 more source